Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 2000 Oct;76(900):625–628. doi: 10.1136/pmj.76.900.625

Association of anticardiolipin antibodies with vascular injury: possible mechanisms

Y Haviv 1
PMCID: PMC1741764  PMID: 11009576

Full Text

The Full Text of this article is available as a PDF (87.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amengual O., Atsumi T., Khamashta M. A., Tinahones F., Hughes G. R. Autoantibodies against oxidized low-density lipoprotein in antiphospholipid syndrome. Br J Rheumatol. 1997 Sep;36(9):964–968. doi: 10.1093/rheumatology/36.9.964. [DOI] [PubMed] [Google Scholar]
  2. Appleton I., Brown N. J., Willis D., Colville-Nash P. R., Alam C., Brown J. R., Willoughby D. A. The role of vascular endothelial growth factor in a murine chronic granulomatous tissue air pouch model of angiogenesis. J Pathol. 1996 Sep;180(1):90–94. doi: 10.1002/(SICI)1096-9896(199609)180:1<90::AID-PATH615>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  3. Arese M., Strasly M., Ruva C., Costamagna C., Ghigo D., MacAllister R., Verzetti G., Tetta C., Bosia A., Bussolino F. Regulation of nitric oxide synthesis in uraemia. Nephrol Dial Transplant. 1995;10(8):1386–1397. [PubMed] [Google Scholar]
  4. Arnout J. The pathogenesis of the antiphospholipid syndrome: a hypothesis based on parallelisms with heparin-induced thrombocytopenia. Thromb Haemost. 1996 Apr;75(4):536–541. [PubMed] [Google Scholar]
  5. Atsumi T., Khamashta M. A., Amengual O., Donohoe S., Mackie I., Ichikawa K., Koike T., Hughes G. R. Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol. 1998 May;112(2):325–333. doi: 10.1046/j.1365-2249.1998.00582.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Atsumi T., Khamashta M. A., Andujar C., Leandro M. J., Amengual O., Ames P. R., Hughes G. R. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome. J Rheumatol. 1998 Jan;25(1):69–73. [PubMed] [Google Scholar]
  7. Atsumi T., Khamashta M. A., Haworth R. S., Brooks G., Amengual O., Ichikawa K., Koike T., Hughes G. R. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum. 1998 May;41(5):800–807. doi: 10.1002/1529-0131(199805)41:5<800::AID-ART5>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  8. BOWIE E. J., THOMPSON J. H., Jr, PASCUZZI C. A., OWEN C. A., Jr THROMBOSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS DESPITE CIRCULATING ANTICOAGULANTS. J Lab Clin Med. 1963 Sep;62:416–430. [PubMed] [Google Scholar]
  9. Bacharach J. M., Lie J. T., Homburger H. A. The prevalence of vascular occlusive disease associated with antiphospholipid syndromes. Int Angiol. 1992 Jan-Mar;11(1):51–56. [PubMed] [Google Scholar]
  10. Blank M., Faden D., Tincani A., Kopolovic J., Goldberg I., Gilburd B., Allegri F., Balestrieri G., Valesini G., Shoenfeld Y. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun. 1994 Aug;7(4):441–455. doi: 10.1006/jaut.1994.1032. [DOI] [PubMed] [Google Scholar]
  11. Cockwell P., Tse W. Y., Savage C. O. Activation of endothelial cells in thrombosis and vasculitis. Scand J Rheumatol. 1997;26(3):145–150. doi: 10.3109/03009749709065673. [DOI] [PubMed] [Google Scholar]
  12. Couffinhal T., Kearney M., Witzenbichler B., Chen D., Murohara T., Losordo D. W., Symes J., Isner J. M. Vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) in normal and atherosclerotic human arteries. Am J Pathol. 1997 May;150(5):1673–1685. [PMC free article] [PubMed] [Google Scholar]
  13. Davies M. G., Hagen P. O. Alterations in venous endothelial cell and smooth muscle cell relaxation induced by high glucose concentrations can be prevented by aminoguanidine. J Surg Res. 1996 Jul 1;63(2):474–479. doi: 10.1006/jsre.1996.0295. [DOI] [PubMed] [Google Scholar]
  14. Del Papa N., Meroni P. L., Tincani A., Harris E. N., Pierangeli S. S., Barcellini W., Borghi M. O., Balestrieri G., Zanussi C. Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol. 1992 Jan-Feb;10(1):37–42. [PubMed] [Google Scholar]
  15. Del Papa N., Raschi E., Catelli L., Khamashta M. A., Ichikawa K., Tincani A., Balestrieri G., Meroni P. L. Endothelial cells as a target for antiphospholipid antibodies: role of anti-beta 2 glycoprotein I antibodies. Am J Reprod Immunol. 1997 Sep;38(3):212–217. doi: 10.1111/j.1600-0897.1997.tb00301.x. [DOI] [PubMed] [Google Scholar]
  16. Del Papa N., Sheng Y. H., Raschi E., Kandiah D. A., Tincani A., Khamashta M. A., Atsumi T., Hughes G. R., Ichikawa K., Koike T. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol. 1998 Jun 1;160(11):5572–5578. [PubMed] [Google Scholar]
  17. Del Papa N., Sheng Y. H., Raschi E., Kandiah D. A., Tincani A., Khamashta M. A., Atsumi T., Hughes G. R., Ichikawa K., Koike T. Human beta 2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-beta 2-glycoprotein I antibodies. J Immunol. 1998 Jun 1;160(11):5572–5578. [PubMed] [Google Scholar]
  18. Exner T., Triplett D. A., Taberner D., Machin S. J. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost. 1991 Mar 4;65(3):320–322. [PubMed] [Google Scholar]
  19. Frostegård J., Wu R., Giscombe R., Holm G., Lefvert A. K., Nilsson J. Induction of T-cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992 Apr;12(4):461–467. doi: 10.1161/01.atv.12.4.461. [DOI] [PubMed] [Google Scholar]
  20. Funauchi M., Hamada K., Enomoto H., Ikoma S., Ohno M., Kinoshita K., Horiuchi A. Characteristics of the clinical findings in patients with idiopathic thrombocytopenic purpura who are positive for anti-phospholipid antibodies. Intern Med. 1997 Dec;36(12):882–885. doi: 10.2169/internalmedicine.36.882. [DOI] [PubMed] [Google Scholar]
  21. García-Martín F., De Arriba G., Carrascosa T., Moldenhauer F., Martin-Escobar E., Val J., Saiz F. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant. 1991;6(8):543–547. doi: 10.1093/ndt/6.8.543. [DOI] [PubMed] [Google Scholar]
  22. George J., Blank M., Hojnik M., Bar-Meir E., Koike T., Matsuura E., Lorber M., Aviram M., Shoenfeld Y. Oxidized low-density lipoprotein (Ox-LDL) but not LDL aggravates the manifestations of experimental antiphospholipid syndrome (APS). Clin Exp Immunol. 1997 May;108(2):227–233. doi: 10.1046/j.1365-2249.1997.d01-1019.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. George J., Harats D., Gilburd B., Shoenfeld Y. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis. Immunol Res. 1996;15(4):315–322. doi: 10.1007/BF02935315. [DOI] [PubMed] [Google Scholar]
  24. Gharavi A. E., Sammaritano L. R., Wen J., Elkon K. B. Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H). J Clin Invest. 1992 Sep;90(3):1105–1109. doi: 10.1172/JCI115927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Hojnik M., George J., Ziporen L., Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996 Apr 15;93(8):1579–1587. doi: 10.1161/01.cir.93.8.1579. [DOI] [PubMed] [Google Scholar]
  26. Hunt J. E., Simpson R. J., Krilis S. A. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2141–2145. doi: 10.1073/pnas.90.6.2141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Hörkkö S., Miller E., Dudl E., Reaven P., Curtiss L. K., Zvaifler N. J., Terkeltaub R., Pierangeli S. S., Branch D. W., Palinski W. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 1996 Aug 1;98(3):815–825. doi: 10.1172/JCI118854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kabakov A. E., Tertov V. V., Saenko V. A., Poverenny A. M., Orekhov A. N. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol. 1992 Jun;63(3):214–220. doi: 10.1016/0090-1229(92)90225-d. [DOI] [PubMed] [Google Scholar]
  29. Koike T., Matsuura E. beta 2-Glycoprotein I and antiphospholipid syndrome. Isr J Med Sci. 1997 Apr;33(4):225–238. [PubMed] [Google Scholar]
  30. Koike T. [Autoantibodies and thrombosis]. Hokkaido Igaku Zasshi. 1997 Sep;72(5):485–490. [PubMed] [Google Scholar]
  31. Levy P. J., Gonzalez M. F., Hornung C. A., Chang W. W., Haynes J. L., Rush D. S. A prospective evaluation of atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity atherosclerosis. J Vasc Surg. 1996 Jan;23(1):36-43, discussion 43-5. doi: 10.1016/s0741-5214(05)80033-3. [DOI] [PubMed] [Google Scholar]
  32. Lyons T. J. Lipoprotein glycation and its metabolic consequences. Diabetes. 1992 Oct;41 (Suppl 2):67–73. doi: 10.2337/diab.41.2.s67. [DOI] [PubMed] [Google Scholar]
  33. Martinuzzo M. E., Forastiero R. R., Carreras L. O. Anti beta 2 glycoprotein I antibodies: detection and association with thrombosis. Br J Haematol. 1995 Feb;89(2):397–402. doi: 10.1111/j.1365-2141.1995.tb03317.x. [DOI] [PubMed] [Google Scholar]
  34. Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Suzuki T., Sumida T., Yasuda T., Koike T. Heterogeneity of anticardiolipin antibodies defined by the anticardiolipin cofactor. J Immunol. 1992 Jun 15;148(12):3885–3891. [PubMed] [Google Scholar]
  35. Nesher G., Ilany J., Rosenmann D., Abraham A. S. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum. 1997 Aug;27(1):27–35. doi: 10.1016/s0049-0172(97)80034-0. [DOI] [PubMed] [Google Scholar]
  36. Ooi B. S., Papademetrious V., Cohen D. J. Demonstration of endothelial-activating properties of hypertensive sera. Am J Hypertens. 1996 Dec;9(12 Pt 1):1232–1235. doi: 10.1016/S0895-7061(96)00329-9. [DOI] [PubMed] [Google Scholar]
  37. Oosting J. D., Derksen R. H., Bobbink I. W., Hackeng T. M., Bouma B. N., de Groot P. G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993 May 15;81(10):2618–2625. [PubMed] [Google Scholar]
  38. Pidwell D. J., Heller M. J., Gabler D., Orosz C. G. In vitro stimulation of human endothelial cells by sera from a subpopulation of high-percentage panel-reactive antibody patients. Transplantation. 1995 Sep 27;60(6):563–569. doi: 10.1097/00007890-199509270-00008. [DOI] [PubMed] [Google Scholar]
  39. Rauch J., Janoff A. S. Antibodies against phospholipids other than cardiolipin: potential roles for both phospholipid and protein. Lupus. 1996 Oct;5(5):498–502. doi: 10.1177/096120339600500534. [DOI] [PubMed] [Google Scholar]
  40. Roubey R. A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 1994 Nov 1;84(9):2854–2867. [PubMed] [Google Scholar]
  41. Sammaritano L. R., Lockshin M. D., Gharavi A. E. Antiphospholipid antibodies differ in aPL cofactor requirement. Lupus. 1992 Feb;1(2):83–90. doi: 10.1177/096120339200100205. [DOI] [PubMed] [Google Scholar]
  42. Schved J. F., Dupuy-Fons C., Biron C., Quére I., Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis. 1994 May-Jun;24(3):175–182. doi: 10.1159/000217099. [DOI] [PubMed] [Google Scholar]
  43. Sebastiani G. D., Galeazzi M., Morozzi G., Marcolongo R. The immunogenetics of the antiphospholipid syndrome, anticardiolipin antibodies, and lupus anticoagulant. Semin Arthritis Rheum. 1996 Jun;25(6):414–420. doi: 10.1016/s0049-0172(96)80006-0. [DOI] [PubMed] [Google Scholar]
  44. Shoenfeld Y., Isenberg D. A. The mosaic of autoimmunity. Immunol Today. 1989 Apr;10(4):123–126. doi: 10.1016/0167-5699(89)90245-4. [DOI] [PubMed] [Google Scholar]
  45. Sitter T., Schiffl H. Anticardiolipin antibodies in patients on regular hemodialysis: an epiphenomenon? Nephron. 1993;64(4):655–656. doi: 10.1159/000187422. [DOI] [PubMed] [Google Scholar]
  46. Stemme S., Faber B., Holm J., Wiklund O., Witztum J. L., Hansson G. K. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3893–3897. doi: 10.1073/pnas.92.9.3893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Takeya H., Tanaka Y., Suzuki K. [Thrombosis and apoptosis]. Rinsho Byori. 1997 Jul;45(7):614–620. [PubMed] [Google Scholar]
  48. Taylor L. M., Jr, Chitwood R. W., Dalman R. L., Sexton G., Goodnight S. H., Porter J. M. Antiphospholipid antibodies in vascular surgery patients. A cross-sectional study. Ann Surg. 1994 Oct;220(4):544–551. doi: 10.1097/00000658-199410000-00012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Trent K., Neustater B. R., Lottenberg R. Chronic relapsing thrombotic thrombocytopenic purpura and antiphospholipid antibodies: a report of two cases. Am J Hematol. 1997 Feb;54(2):155–159. doi: 10.1002/(sici)1096-8652(199702)54:2<155::aid-ajh10>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  50. Tyagi S. C., Smiley L. M., Mujumdar V. S., Clonts B., Parker J. L. Reduction-oxidation (Redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Mol Cell Biochem. 1998 Apr;181(1-2):107–116. doi: 10.1023/a:1006882014593. [DOI] [PubMed] [Google Scholar]
  51. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993 Apr 10;341(8850):923–925. doi: 10.1016/0140-6736(93)91213-6. [DOI] [PubMed] [Google Scholar]
  52. Vermylen J., Arnout J. Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med. 1992 Jul;120(1):10–12. [PubMed] [Google Scholar]
  53. Westerman E. M., Miles J. M., Backonja M., Sundstrom W. R. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event. Arthritis Rheum. 1992 Sep;35(9):1038–1041. doi: 10.1002/art.1780350908. [DOI] [PubMed] [Google Scholar]
  54. Wilson W. A. Histocompatibility genes in antiphospholipid antibody syndrome. Lupus. 1996 Aug;5(4):259–262. doi: 10.1177/096120339600500403. [DOI] [PubMed] [Google Scholar]
  55. Ylä-Herttuala S., Palinski W., Butler S. W., Picard S., Steinberg D., Witztum J. L. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994 Jan;14(1):32–40. doi: 10.1161/01.atv.14.1.32. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES